Bevespi Aerosphere – a Dual BronchodilatorDear Dr. Mahler:
When will bevespi aerosphere be available?
Kenneth from Orange, MA
Bevespi Aerosphere is an inhaler approved on April 25, 2016, by the U.S. Food and Drug Administration for use in those with COPD.
What is Bevespi Aerosphere? It contains two different bronchodilators that act to relax muscles that wraps around breathing tubes. One medication is called glycopyrrolate – a muscarinic antagonsit – and the other medication is called formoterol – a beta agonist. The two medications are delivered using a unique co-suspension technology. It is to be used twice a day, 12 hours apart.
AstraZeneca is the pharmaceutical company that makes Bevespi. Current plans are that Bevespi will be available in the U.S. in early 2017.Why will it take that long?
Contact AstraZenecaHere is information from their website. If you are in the United States and would like additional information regarding AstraZeneca products, or you are a third party with an offer of services for AstraZeneca, you can contact the AstraZeneca Information Center by phone at 1-800-236-9933 (Monday – Friday 8 a.m. – 6 p.m. ET, excluding holidays).
For the past several years medical insurance companies decide which medications they will cover (pay for) and what medications they will not cover (pay for). These companies have contracts with health care programs like Medicare, Medicaid, Anthem Blue Cross, and many others. These contracts typically start in January and last one year.
It is common that insurance companies have new contracts for preferred bronchodilators each year. This may require those with COPD to change their medication(s) when scheduled to be refilled early in the year. Either you agree to change or else you may have to pay full price out of pocket or have a higher co-pay.
Finally, there are two other dual bronchodilators currently available in the U.S. One is Anoro Ellipta™, a dry powder, and the other is Stiolto Respimat™, a fine mist.
Donald A. Mahler, M.D.